In addressing this risk, anticoagulation therapy has become integral, with direct oral anticoagulants (DOACs) emerging as pivotal agents. Rivaroxaban, a factor Xa inhibitor, stands out among DOACs, demonstrating efficacy in stroke prevention with a potentially more convenient once-a-day dosing regimen [3]. The gene discussed is F10; the disease is Stroke.